新たに診断された GBM の治療のための RT および TMZ を併用した Optune® (腫瘍治療領域) の重要な無作為化非盲検試験 (EF-32)
EF-32: 新たに診断された神経膠芽腫の治療のための放射線療法およびテモゾロミドと併用したOptune® (腫瘍治療フィールド、200kHz) の重要な無作為化非盲検試験
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
調査の概要
詳細な説明
Optune® is a medical device that has been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States. Optune® has obtained a CE mark in Europe for recurrent and newly diagnosed GBM.
The current standard of care for GBM includes the addition of Optune® to maintenance temozolomide (TMZ), following the completion of radiation therapy (RT).
The purpose of the current study is to test if the earlier introduction of Optune®, at the time of radiation therapy (which is given together with temozolomide), improves clinical outcomes compared to the standard of care.
The study will randomize 950 subjects equally to one of two treatment arms:
- Treatment arm I: Patients receive TTFields at 200 kHz to the brain using the Optune® System together with RT and TMZ, followed by maintenance TMZ concomitant with the Optune® treatment.
- Treatment arm II: Patients receive RT and TMZ alone, followed by maintenance TMZ concomitant with TTFields at 200 kHz to the brain using the Optune®.
All patients are to receive standard RT and TMZ treatment followed by maintenance TMZ chemotherapy and Optune® according to the current standard of care regimen.
Optune® will continue until second disease progression per 2010 RANO Criteria unless any of the treatment discontinuation conditions described under criteria for patient withdrawal or termination are met.
After surgery or biopsy, subjects that would like to participate will be required to submit samples of their tumor to a lab for testing. The results of this test will be used for randomization into the trial.
If the subject is assigned to the treatment group that will start Optune® therapy during radiation therapy, Optune® therapy will begin within 10 days of enrolling in the study and no later than the first day of RT and TMZ treatment.
After the initial visit, subjects will continue treatment at home, while pursuing normal daily routines. Subjects are required to use the device for at least 18 hours a day. Short breaks in treatment for personal hygiene and other personal needs is allowed. Total usage time will be recorded and provided to the site and sponsor.
Subjects will be required to return to the clinic per the study protocol.
After the second disease progression, subjects will return to the clinic for one final visit approximately 30 days after the last treatment with Optune® or after second disease progression, the latter of the two per protocol.
After completing active participation in the study, subjects will be contacted once per month to answer basic questions about their health status.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35243
- Grandview Cancer Center
-
-
Arizona
-
Gilbert、Arizona、アメリカ、85234
- Banner MD Anderson Cancer Center
-
Phoenix、Arizona、アメリカ、85054
- Mayo Clinic- Arizona
-
Tucson、Arizona、アメリカ、85719
- University of Arizona Cancer Center
-
-
Arkansas
-
Fayetteville、Arkansas、アメリカ、72762
- Highlands Oncology Group
-
-
California
-
Burbank、California、アメリカ、91505
- Providence St. Joseph Medical Center and The Roy and Patricia Disney Family Cancer Center
-
Duarte、California、アメリカ、91010
- City of Hope National Medical Center
-
Fullerton、California、アメリカ、92835
- TRIO - St. Jude Heritage Healthcare/St. Jude Medical Center
-
La Jolla、California、アメリカ、92093
- University of California at San Diego - Moores Cancer Center
-
Los Angeles、California、アメリカ、90048
- Cedars - Sinai Medical Center
-
Los Angeles、California、アメリカ、90033
- Norris Comprehensive Cancer Center at USC
-
Newport Beach、California、アメリカ、92663
- Hoag Memorial Hospital - Hoag Cancer Center
-
Orange、California、アメリカ、92868
- St. Joseph Hospital of Orange
-
Orange、California、アメリカ、92868
- University of California - Irvine/UCI Medical Center
-
Palo Alto、California、アメリカ、94303
- Stanford University Cancer Institute
-
San Diego、California、アメリカ、92123
- Sharp Memorial Hospital - X-Ray Medical Group Radiation Oncology
-
San Francisco、California、アメリカ、94143
- University of California San Francisco Medical Center
-
Santa Monica、California、アメリカ、90404
- John Wayne Cancer Institute at St. John's Health Center
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado Cancer Center Anschutz
-
Englewood、Colorado、アメリカ、80113
- HCA Research Institute - Blue Sky Neurology - Denver
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06106
- Hartford Healthcare Medical Group - Hartford Hospital The Gray Cancer Center
-
-
Florida
-
Boca Raton、Florida、アメリカ、33486
- Lynn Cancer Institute, Marcus Neuroscience Institute
-
Jacksonville、Florida、アメリカ、32224
- Mayo Clinic
-
Jacksonville、Florida、アメリカ、32207
- Baptist Health - Jacksonville
-
Orlando、Florida、アメリカ、32804
- AdventHealth
-
Orlando、Florida、アメリカ、32806
- Orlando Health UF Health Cancer Center
-
Tampa、Florida、アメリカ、33612
- H. Lee Moffitt Cancer Center and Research Institute, Inc
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30342
- Northside Hospital, Inc.
-
Atlanta、Georgia、アメリカ、30309
- Piedmont Healthcare Brain Tumor Center
-
Atlanta、Georgia、アメリカ、30322
- The Emory Clinic - Emory Healthcare - Winship Cancer Institute
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- Rush University Medical Center
-
Chicago、Illinois、アメリカ、60617
- University of Chicago
-
-
Indiana
-
Fort Wayne、Indiana、アメリカ、46845
- Parkview Cancer Institute - Fort Wayne Radiation Oncology Associates
-
-
Kansas
-
Topeka、Kansas、アメリカ、66606
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40241
- Norton Cancer Institute
-
Louisville、Kentucky、アメリカ、40202
- University of Louisville - James Graham Brown Cancer Center
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70810
- Mary Bird Cancer Center Neuromedical Center
-
New Orleans、Louisiana、アメリカ、70072
- LSU Health Sciences Center, New Orleans
-
New Orleans、Louisiana、アメリカ、70121-2429
- Ochsner Health System
-
-
Maine
-
South Portland、Maine、アメリカ、04106
- Maine Medical Partners Neurology - Neurosurgery & Spine Associates
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- John Hopkins School of Medicine
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02111
- Tufts Medical Center
-
Worcester、Massachusetts、アメリカ、01655
- University of Massachusetts Chan Medical School
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55407
- Abbott Northwestern Hospital - Givens Brain Tumor Center
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia、Missouri、アメリカ、65212
- University of Missouri - Ellis Fischel Cancer Center
-
Kansas City、Missouri、アメリカ、64132
- Health Midwest Ventures Group, Inc - Sarah Cannon HCA Midwest Brain and Spine
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Edison、New Jersey、アメリカ、08820
- JFK Neuroscience Institute, HMH JFK University Medical Center
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University Medical Center - John Theurer Cancer Center
-
Neptune City、New Jersey、アメリカ、07753
- Jersey Shore University Medical Center
-
-
New York
-
Lake Success、New York、アメリカ、11042
- Northwell Health System Brain Tumor Center
-
New York、New York、アメリカ、10029
- Mount Sinai - Icahn School of Medicine
-
New York、New York、アメリカ、10016
- NYU Langone - Laura & Issac Perimutter Cancer Center
-
New York、New York、アメリカ、10032
- New York Presbyterian - Columbia University
-
Rochester、New York、アメリカ、14642
- University of Rochester Medical Center
-
Syracuse、New York、アメリカ、13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center
-
Charlotte、North Carolina、アメリカ、28204
- Novant Health Cancer Institute Radiation Oncology
-
Greenville、North Carolina、アメリカ、27834
- Vidant Medical Center
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest Baptist Comprehensive Cancer Center
-
Winston-Salem、North Carolina、アメリカ、27103
- Forsyth Medical Center-Novant Health
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- University of Cincinnati Cancer Institute
-
Columbus、Ohio、アメリカ、43210
- The James Cancer Hospital and Solove Research Institute - Arthur G James Cancer Hospital
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19107
- Thomas Jefferson University Hospital
-
Philadelphia、Pennsylvania、アメリカ、19104
- Neuroscience Center, Philadelphia - University of Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15232
- UPMC Hillman Cancer Center
-
Pittsburgh、Pennsylvania、アメリカ、15212
- Allegheny Health Network Cancer Institute
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- MUSC Radiation Oncology Brain & Spine Tumor Program
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37404
- SCRI - Tennessee Oncology
-
Germantown、Tennessee、アメリカ、38138
- West Cancer Center - Germantown
-
Nashville、Tennessee、アメリカ、37203
- SCRI - Tennessee Oncology
-
-
Texas
-
Austin、Texas、アメリカ、78705
- Texas Oncology Midtown - Austin Brain Tumor Center
-
Dallas、Texas、アメリカ、75246
- Baylor Charles A. Sammons Cancer Center - Baylor University Medical Center
-
Fort Worth、Texas、アメリカ、76104
- John Peter Smith Health Network - JPS Cancer Center
-
Houston、Texas、アメリカ、77030
- Houston Methodist Hospital
-
Houston、Texas、アメリカ、77030
- UT Health Mischer Neuroscience - Memorial Herman - UT Neurosciences
-
Temple、Texas、アメリカ、76508
- Baylor Scott & White Medical Center
-
-
Vermont
-
Burlington、Vermont、アメリカ、05401
- The University of Vermont Medical Center - University of Vermont Cancer Center
-
-
Washington
-
Seattle、Washington、アメリカ、98122
- Swedish Health Services
-
Seattle、Washington、アメリカ、98109
- UW Medical Center - Alvord Brain Tumor Center
-
-
West Virginia
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Cancer Institute
-
-
-
-
-
Liverpool、イギリス、L7 8YA
- Clatterbridge Cancer Centre
-
London、イギリス、SE1 9RT
- Guy's Hospital
-
London、イギリス、W6 8RF
- Charing Cross Hospital
-
Nottingham、イギリス、NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Preston、イギリス、PR29HT
- Royal Preston Hospital
-
-
-
-
-
Jerusalem、イスラエル、9112001
- Hadassah Medical Center - Ein Kerem
-
-
Haifa District
-
Haifa、Haifa District、イスラエル、3109601
- Rambam Medical Center
-
-
Petah Tikva
-
Petah Tikva、Petah Tikva、イスラエル、49100
- Rabin Medical Center
-
-
Ramat Gan
-
Ramat Gan、Ramat Gan、イスラエル、52621
- Sheba Medical Center
-
-
Tel Aviv
-
Tel Aviv、Tel Aviv、イスラエル、64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
Innsbruck
-
Innsbruck、Innsbruck、オーストリア、6020
- Innsbruck University Hospital
-
-
Linz
-
Linz、Linz、オーストリア、4020
- Kepler University Hospital
-
-
State of Salzburg
-
Salzburg、State of Salzburg、オーストリア、5020
- University Hospital Salzburg
-
-
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 4E6
- BC Cancer - Vancouver
-
-
Nova Scotia
-
Sydney、Nova Scotia、カナダ、B1P 1P3
- Nova Scotia Health Authority
-
-
Ontario
-
Ottawa、Ontario、カナダ
- The Ottawa Hospital Cancer Centre
-
Toronto、Ontario、カナダ
- Princess Margaret Cancer Centre
-
Toronto、Ontario、カナダ
- Sunnybrook Research Institute - Odette Cancer Centre
-
-
Quebec
-
Montreal、Quebec、カナダ、H2X1R9
- CHUM Centre de Recherche
-
Sherbrooke、Quebec、カナダ
- Universite de Sherbrooke - Sherbrooke Centre Hospitalier Universita
-
-
-
-
-
Lausanne、スイス、CH-1011
- Lausanne University Hospital
-
Zurich、スイス、8091
- University Hospital Zurich
-
-
-
-
Brno
-
Brno、Brno、チェコ、656 53
- Masaryk Memorial Cancer Institute
-
-
Pilsen
-
Pilsen、Pilsen、チェコ、305 99
- University Hospital Plzeň
-
-
Prague
-
Prague、Prague、チェコ、150 30
- Na Homolce Hospital
-
-
-
-
-
Essen、ドイツ、45147
- University Hospital Essen
-
Freiburg im Breisgau、ドイツ、79106
- University Medical Center Freiburg
-
Leipzig、ドイツ、04103
- University Hospital Leipzig
-
Munich、ドイツ、81675
- Rechts der Isar Hospital
-
Tübingen、ドイツ、72076
- University Hospital Tübingen
-
-
-
-
-
Angers、フランス、49055
- Institut de cancérologie de l'Ouest
-
Bron、フランス、69677
- Pierre Wertheimer Hospital
-
Marseille、フランス、13305
- Hôpital la Timone
-
Nice、フランス、06000
- University Hospital Nice
-
Paris、フランス、75013
- Pitié-Salpêtrière University Hospital
-
Saint-Herblain、フランス、44800
- Institut de cancérologie de l'Ouest
-
Toulouse、フランス、31059
- University Institute Cancer Toulouse Oncopole
-
Villejuif、フランス、94805
- Gustave Roussy Institute
-
-
-
-
-
Liège、ベルギー、B35, 4000
- University Hospital Liege - Sart Tilman
-
-
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、060-8648
- Hokkaido University Hospital
-
-
Ishikawa-ken
-
Kanazawa、Ishikawa-ken、日本、920-8641
- Kanazawa University Hospital
-
-
Saitama
-
Hidaka-shi、Saitama、日本、350-1298
- Saitama Medical University International Medical Center
-
-
Tokyo-To
-
Mitaka-shi、Tokyo-To、日本、181-8611
- Kyorin University Hospital
-
Shinjuku-ku、Tokyo-To、日本、162-8666
- Tokyo Women's Medical University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
*Age Limits - 18 years or older outside of the US, 22 years or older within the US.
Inclusion Criteria:
- Histologically confirmed diagnosis of GBM according to WHO 2016 classification criteria.
- Age ≥ 22 years in US and Age ≥ 18 years in Ex-US
- Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection, and biopsy-only patients are all acceptable)
- Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
- Karnofsky performance status ≥ 70
- Life expectancy ≥ least 3 months
- Participants of childbearing age must use highly effective contraception. An effective method of birth control is defined as one that results in a failure rate of less than 1% per year when used consistently and correctly. The Investigator must approve the selected method, and may consult with a gynecologist as needed.
- All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
- Stable or decreasing dose of corticosteroids for the last 7 days prior to randomization, if applicable.
- Concomitant RT with TMZ treatment planned to start no later than 8 weeks from surgery
- Women of childbearing potential must have a negative β-HCG pregnancy test documented within 14 days prior to randomization
- Is able to have MRI with contrast of the brain
Exclusion Criteria:
-
Progressive disease (per investigator's assessment)
-
Infratentorial or leptomeningeal disease
-
Participation in another clinical treatment study during the pre-treatment and/or the treatment phase of the study
-
Pregnancy or breast-feeding.
-
Significant co-morbidities at baseline which would preclude maintenance RT or TMZ treatment, as determined by the investigator:
- Thrombocytopenia (platelet count < 100 x 103/μL)
- Neutropenia (absolute neutrophil count < 1.5 x 103/μL)
- CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)
- Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
- Total bilirubin > 1.5 x upper limit of normal
- Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 µmol/l)
- History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
-
Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.
-
Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
-
History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC.
-
Additional malignancies that are progressing or required active treatment in the last two years.
-
Admitted to an institution by administrative or court order.
-
Known allergies to medical adhesives or hydrogel
-
A skull defect (such as, missing bone with no replacement)
-
Prior radiation treatment to the brain for the treatment of GBM
-
Any serious surgical/post-operative condition that may put the participant at risk according to the investigator.
-
Standard TTFields exclusion criteria include
- Active implanted medical devices
- Bullet fragments
- Skull defects
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Optune® + RT + TMZ for 6 weeks
Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
|
アクティブコンパレータ:RT +TMZ for 6 weeks
RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:5 years
|
Survival will be measured from the time of randomization until date patient is alive. |
5 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival (PFS)
時間枠:5 years
|
PFS will be measured from the date of randomization to the date of progression based on the 2010 RANO Criteria. |
5 years
|
|
1- and 2-year survival rates
時間枠:5 years
|
The analyses will be performed based on estimated proportions of patients who are on study at 12 and 24 months in both arms of the study. |
5 years
|
|
Overall Radiological response (ORR)
時間枠:5 years
|
The analyses will be performed based on the 2010 RANO criteria, and comparison between the rates of response. |
5 years
|
|
Next progression-free survival (PFS2)
時間枠:5 years
|
PFS2 will be measured from the time of randomization to second tumor progression. |
5 years
|
|
Progression-free survival at 6 (PFS6) and 12 months (PFS12)
時間枠:5 years
|
The analyses will be estimated proportions of patients who are progression-free at 6 and 12 months in both arms of the study. |
5 years
|
|
Severity and frequency of adverse events
時間枠:5 years
|
The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments. |
5 years
|
|
Quality of Life EORTC Questionnaire
時間枠:5 years
|
The analyses will be assessed using the EORTC QLQ C-30 questionnaire with BN-20 (brain symptom) supplement. |
5 years
|
|
The NANO scale
時間枠:5 years
|
The Neurological assessment in Neuro-Oncology will be assessed using the NANO scale questionnaire and per the 2010 RANO criteria. |
5 years
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Miller R, Niazi M, Russial O, Poiset S, Shi W. Tumor treating fields with radiation for glioblastoma: a narrative review. Chin Clin Oncol. 2022 Oct;11(5):40. doi: 10.21037/cco-22-90.
- Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N, Glass J, Alnahhas I, Andrews D, Judy K, Evans J, Farrell C, Werner-Wasik M, Chervoneva I, Ly M, Palmer J, Liu H, Shi W. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. Front Oncol. 2022 Apr 29;12:896246. doi: 10.3389/fonc.2022.896246. eCollection 2022.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。